Axcella Health Inc., a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States.
Adequate balance sheet and overvalued.
Share Price & News
How has Axcella Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AXLA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AXLA underperformed the US Biotechs industry which returned 27.2% over the past year.
Return vs Market: AXLA underperformed the US Market which returned 14.9% over the past year.
Price Volatility Vs. Market
How volatile is Axcella Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Type Of Shareholders Make Up Axcella Health Inc.'s (NASDAQ:AXLA) Share Registry?
2 months ago | Simply Wall StChairman David Epstein Just Bought 73% More Shares In Axcella Health Inc. (NASDAQ:AXLA)
3 months ago | Simply Wall StWhat Percentage Of Axcella Health Inc. (NASDAQ:AXLA) Shares Do Insiders Own?
Is Axcella Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AXLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AXLA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AXLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AXLA is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.3x).
How is Axcella Health forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AXLA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AXLA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AXLA's Return on Equity is forecast to be high in 3 years time
How has Axcella Health performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AXLA is currently unprofitable.
Growing Profit Margin: AXLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AXLA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AXLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).
Return on Equity
High ROE: AXLA has a negative Return on Equity (-133.45%), as it is currently unprofitable.
How is Axcella Health's financial position?
Financial Position Analysis
Short Term Liabilities: AXLA's short term assets ($76.8M) exceed its short term liabilities ($7.0M).
Long Term Liabilities: AXLA's short term assets ($76.8M) exceed its long term liabilities ($23.7M).
Debt to Equity History and Analysis
Debt Level: AXLA's debt to equity ratio (53.4%) is considered high.
Reducing Debt: Insufficient data to determine if AXLA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXLA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AXLA is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
What is Axcella Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AXLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AXLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AXLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXLA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AXLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Hinshaw (51 yo)
Mr. William R. Hinshaw, Jr, also known as Bill, has been President, Chief Executive Officer and Director of Axcella Health Inc. since June 2018. Prior to this role, Mr. Hinshaw held a number of leadership ...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD1.35M) is about average for companies of similar size in the US market ($USD1.33M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
|Chief Medical Officer & Senior VP of Clinical Development||3yrs||US$1.71m||no data|
|Executive VP & Chief Development Officer||1.58yrs||US$3.91m||no data|
|Senior VP & CFO||0.75yr||no data||0.010% |
|Chief Scientific Officer and Senior VP of Research & Development||3.17yrs||no data||no data|
|Senior VP of Legal||0.75yr||no data||no data|
|Senior VP & Chief People Officer||0.17yr||no data||no data|
|Global Head of Regulatory Affairs & Pharmacovigilance and Senior Vice President||5.17yrs||no data||no data|
|Senior VP & Chief Business Officer||2yrs||US$892.67k||no data|
|Senior VP & Chief Intellectual Property Officer||2.33yrs||no data||no data|
Experienced Management: AXLA's management team is considered experienced (2.1 years average tenure).
|Independent Director||2.17yrs||US$146.43k||no data|
|Independent Director||1yr||US$133.08k||0.0028% |
|Independent Director||8.83yrs||US$131.43k||no data|
|Independent Director||6.25yrs||US$129.55k||no data|
|Independent Director||2.17yrs||US$131.30k||no data|
|Independent Director||4.5yrs||US$131.43k||no data|
Experienced Board: AXLA's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AXLA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.8%.
Axcella Health Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Axcella Health Inc.
- Ticker: AXLA
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$160.916m
- Shares outstanding: 35.84m
- Website: https://www.axcellahealth.com
Number of Employees
- Axcella Health Inc.
- 840 Memorial Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AXLA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2019|
Axcella Health Inc., a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/04 00:20|
|End of Day Share Price||2020/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.